Source: ERS Skills course: Multi-disciplinary care in thoracic oncology
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
Dimitrios Vassos (Athens, Greece). Pulmonary toxicity. ERS Skills course: Multi-disciplinary care in thoracic oncology

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary toxicity to mesalazine Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Pulmonary hemodynamics and lung function in patients with COPD and DPLD Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Long-term screening for pulmonary hypertension after pulmonary embolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Impact of sepsis in respiratory mechanics of pulmonary arterial hypertension rat model. Preliminary results Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary fibrosis Source: Eur Respir Mon; 2009: 45: 46–53 Year: 2009 Chemotherapy-induced pulmonary hypertension: Role of alkylating agents Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Pulmonary arterial hypertension – A single-centre experience Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Non-invasive cardiac output assessment in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 The incidence of chronic thromboembolic pulmonary hypertension in asympthomatic pulmonary embolism patients Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 The evolution of effort tolerance and body composition in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Cerebral tissue oxygenation in arterial and thromboembolic pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014